Lung Cancer Clinical Trials in Denver

Showing 201-220 of 667 trials

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

NCT05565417

This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas. The main goals of this study are to: * Find the recommended dose of IMT-009 that can be safely given to participants * Learn more about the side effects of IMT-009 * Learn more about pharmacokinetics of IMT-009 * Learn more about the effectiveness of IMT-009 * Learn more about different pharmacokinetic biomarkers and how they might change in the presence of IMT-009

Non Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaTriple Negative Breast Cancer+9 more

Immunitas Therapeutics67 participantsStarted Nov 2022

Tucson, Arizona, United States • Denver, Colorado, United States • Orlando, Florida, United States +6 more locations

COMPLETEDPhase 25.0 miles

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT02186847

This randomized phase II trial studies how well chemotherapy and radiation therapy given with or without metformin hydrochloride works in treating patients with stage III non-small cell lung cancer. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Metformin hydrochloride may shrink tumors and keep them from coming back. It is not yet known whether chemotherapy and radiation therapy is more effective when given with or without metformin hydrochloride in treating stage III non-small cell lung cancer.

Adenosquamous Lung CarcinomaBronchioloalveolar CarcinomaLarge Cell Lung Carcinoma+6 more

NRG Oncology170 participantsStarted Aug 2014

Tuscaloosa, Alabama, United States • Tucson, Arizona, United States • Auburn, California, United States +221 more locations

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer

Lung Cancer Trials in Other Cities

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)

Study With Various Immunotherapy Treatments in Participants With Lung Cancer

Gilteritinib for the Treatment of ALK NSCLC

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations

Other Conditions in Denver